NL193821C - Farmaceutisch preparaat. - Google Patents
Farmaceutisch preparaat. Download PDFInfo
- Publication number
- NL193821C NL193821C NL8203457A NL8203457A NL193821C NL 193821 C NL193821 C NL 193821C NL 8203457 A NL8203457 A NL 8203457A NL 8203457 A NL8203457 A NL 8203457A NL 193821 C NL193821 C NL 193821C
- Authority
- NL
- Netherlands
- Prior art keywords
- ranitidine
- indomethacin
- pharmaceutical preparation
- hydrochloride
- ibuprofen
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 7
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 229960000620 ranitidine Drugs 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 9
- 229960001680 ibuprofen Drugs 0.000 claims description 9
- 229960000905 indomethacin Drugs 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 claims description 8
- 229960001520 ranitidine hydrochloride Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000007903 gelatin capsule Substances 0.000 claims description 3
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- PYJKOOVTHGWGQL-UHFFFAOYSA-N 1-N'-ethyl-1-N'-methyl-2-nitroethane-1,1-diamine Chemical compound C(C)N(C(C[N+](=O)[O-])N)C PYJKOOVTHGWGQL-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- -1 tableting aids Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8126786 | 1981-09-04 | ||
| GB8126786 | 1981-09-04 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NL8203457A NL8203457A (nl) | 1983-04-05 |
| NL193821B NL193821B (nl) | 2000-08-01 |
| NL193821C true NL193821C (nl) | 2000-12-04 |
Family
ID=10524316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8203457A NL193821C (nl) | 1981-09-04 | 1982-09-03 | Farmaceutisch preparaat. |
Country Status (15)
| Country | Link |
|---|---|
| JP (1) | JPS5865215A (it) |
| AU (1) | AU564018B2 (it) |
| BE (1) | BE894285A (it) |
| CH (1) | CH652304A5 (it) |
| DE (1) | DE3232830C2 (it) |
| FR (1) | FR2512342B1 (it) |
| HK (1) | HK91387A (it) |
| IE (1) | IE54149B1 (it) |
| IT (1) | IT1208432B (it) |
| KE (1) | KE3739A (it) |
| MY (1) | MY8700560A (it) |
| NL (1) | NL193821C (it) |
| SE (1) | SE8205034L (it) |
| SG (1) | SG59387G (it) |
| ZA (1) | ZA826477B (it) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8516083D0 (en) * | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
| JPH01197444A (ja) * | 1986-03-04 | 1989-08-09 | Bristol Myers Co | 非ステロイド系抗炎症組成物によって生じる消化管損傷に対するβ−アドレナリン作用薬とある種のヒスタミンＨ↓１−および／またはＨ↓２−受容体遮断薬との組合せの効果 |
| AU627775B2 (en) * | 1988-09-20 | 1992-09-03 | Glaxo Group Limited | Pharmaceutical compositions |
| CA2370268A1 (en) * | 1999-04-19 | 2000-10-26 | Richard Weisbart | Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2360306A1 (fr) * | 1976-08-03 | 1978-03-03 | Huguet Georgette | Nouveaux medicaments antalgiques, antiseptiques et anti-inflammatoires |
| GB1565966A (en) * | 1976-08-04 | 1980-04-23 | Allen & Hanburys Ltd | Aminoalkyl furan derivatives |
-
1982
- 1982-09-02 BE BE0/208936A patent/BE894285A/fr not_active IP Right Cessation
- 1982-09-03 SE SE8205034A patent/SE8205034L/xx unknown
- 1982-09-03 CH CH5245/82A patent/CH652304A5/fr not_active IP Right Cessation
- 1982-09-03 ZA ZA826477A patent/ZA826477B/xx unknown
- 1982-09-03 IT IT8249071A patent/IT1208432B/it active
- 1982-09-03 AU AU87997/82A patent/AU564018B2/en not_active Expired
- 1982-09-03 DE DE3232830A patent/DE3232830C2/de not_active Expired - Lifetime
- 1982-09-03 FR FR8215042A patent/FR2512342B1/fr not_active Expired
- 1982-09-03 JP JP57153791A patent/JPS5865215A/ja active Pending
- 1982-09-03 IE IE2152/82A patent/IE54149B1/en not_active IP Right Cessation
- 1982-09-03 NL NL8203457A patent/NL193821C/nl not_active IP Right Cessation
-
1987
- 1987-07-10 KE KE3739A patent/KE3739A/xx unknown
- 1987-07-22 SG SG593/87A patent/SG59387G/en unknown
- 1987-12-03 HK HK913/87A patent/HK91387A/xx not_active IP Right Cessation
- 1987-12-30 MY MY560/87A patent/MY8700560A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK91387A (en) | 1987-12-11 |
| FR2512342A1 (fr) | 1983-03-11 |
| DE3232830A1 (de) | 1983-03-24 |
| BE894285A (fr) | 1983-03-02 |
| IT8249071A0 (it) | 1982-09-03 |
| SE8205034L (sv) | 1983-03-05 |
| SG59387G (en) | 1987-10-23 |
| FR2512342B1 (fr) | 1986-09-05 |
| SE8205034D0 (sv) | 1982-09-03 |
| JPS5865215A (ja) | 1983-04-18 |
| CH652304A5 (fr) | 1985-11-15 |
| DE3232830C2 (de) | 1994-12-08 |
| KE3739A (en) | 1987-09-04 |
| IT1208432B (it) | 1989-06-12 |
| NL193821B (nl) | 2000-08-01 |
| NL8203457A (nl) | 1983-04-05 |
| MY8700560A (en) | 1987-12-31 |
| AU564018B2 (en) | 1987-07-30 |
| IE54149B1 (en) | 1989-07-05 |
| IE822152L (en) | 1983-03-04 |
| ZA826477B (en) | 1984-04-25 |
| AU8799782A (en) | 1983-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2105193A (en) | Pharmaceutical compositions containing non-steroidal anti-inflammatory agents | |
| US20070128276A1 (en) | Controlled release compositions comprising nimesulide | |
| EP0550083B1 (en) | Medicaments for treating inflammatory conditions or for analgesia containing a NSAID and ranitidine bismuth citrate | |
| CZ298598A3 (cs) | Kombinovaný preparát obsahující /4-trifluormethyl/-anilid kyseliny 5-methylisoxazol-4-katboxylové a amid kyseliny N-/4-trifluormethylfenyl/-2-kyan-3-hydroxykrotonové | |
| JPS61197517A (ja) | 薬剤組成物 | |
| JP2769696B2 (ja) | 月経困難症及び／又は月経前症候群の軽減用薬剤組成物とその調製法 | |
| US4766117A (en) | Antiinflammatory compositions and methods | |
| NL193821C (nl) | Farmaceutisch preparaat. | |
| FR2904774A1 (fr) | Composition pharmaceutique solide contenant une combinaison d'un agent regulateur de la motilite intestinale et d'un antiflatulent. | |
| FR2837706A1 (fr) | Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles | |
| NL9101533A (nl) | Farmaceutische samenstellingen die furaanderivaten bevatten. | |
| JPH0428245B2 (it) | ||
| HU228026B1 (en) | Compositions comprising an hiv protease inhibitor and a water soluble vitamin e compound | |
| US4687766A (en) | Pharmaceutical preparation for the therapeutic treatment of rheumatic diseases | |
| US4880742A (en) | Prostaglandin biosynthesis inhibitors | |
| NL8900525A (nl) | Geneesmiddelen die sufotidine bevatten alsmede de toepassing daarvan. | |
| EP0017169B1 (en) | Improved anti-inflammatory combinations having reduced ulcerogenicity | |
| DE19849737A1 (de) | Kombinationsmittel zur Behandlung entzündlicher Darmerkrankungen | |
| US4874757A (en) | Antinflammatory compositions and methods | |
| NL8203456A (nl) | Farmaceutische preparaten. | |
| EP0182569B1 (en) | Use of 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4H-pyrido[1,2-a]pyrimidine-3-carboxamide for the prevention and treatment of gastrointestinal damages | |
| JP2900056B2 (ja) | 非ステロイド抗炎症剤により生じる胃疾患の予防用医薬組成物 | |
| US4237159A (en) | Novel anti-inflammatory composition | |
| EP0178122A2 (en) | Improved piroxicam-containing antiinflammatory compositions | |
| WO2024129619A1 (en) | Stat3 inhibitors for use in the treatment of non-viral liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| V4 | Discontinued because of reaching the maximum lifetime of a patent |
Free format text: 20020903 |